Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.40 |
| ▸ | UBE2M | P61081 | 6/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 2/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148326 | 0.83 | TACR1 (0.39) | TACR1UBE2MDCUN1D1S1PR1SERPINE1 | |
| SCHEMBL5148339 | 0.81 | GPBAR1 (0.42) | TACR1GPBAR1RXRARXRBRXRG | |
| SCHEMBL5148341 | 0.79 | RXRA (0.35) | TACR1UBE2MDCUN1D1RXRARXRG | |
| SCHEMBL5148343 | 0.75 | TACR1 (0.40) | TACR1SERPINE1 | |
| SCHEMBL5149890 | 0.74 | TACR1 (0.39) | TACR1UBE2MDCUN1D1SERPINE1 | |
| SCHEMBL5148340 | 0.74 | TACR1 (0.41) | TACR1SERPINE1 | |
| SCHEMBL1898562 | 0.74 | CETP (0.53) | — | |
| SCHEMBL5147175 | 0.73 | TACR1 (0.46) | TACR1UBE2MDCUN1D1SERPINE1GPBAR1 | |
| SCHEMBL1893337 | 0.73 | TACR1 (0.44) | TACR1SERPINE1 | |
| SCHEMBL5150827 | 0.72 | UBE2M (0.34) | TACR1UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316447-A1 | Method of inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | TACR1 1329/4885UBE2M 2671/4885DCUN1D1 4486/4885 |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | TACR1 1329/4885UBE2M 2671/4885DCUN1D1 4486/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | TACR1 656/4885UBE2M 3878/4885DCUN1D1 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.